Kymab Overview
- Year Founded
-
2010

- Status
-
Acquired/Merged
- Employees
-
141

- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$1.45B
Kymab General Information
Description
Developer of novel human antibody-based therapies in a broad range of indications. The company offers fully human monoclonal antibody therapeutics to maximize the diversity of human antibodies produced in response to immunization with antigens, thereby enabling healthcare providers to use novel therapeutic antibodies to cure cancer and autoimmune hematological diseases.
Contact Information
Website
www.kymab.comCorporate Office
- The Bennet Building (B930)
- Babraham Research Campus
- Cambridge CB22 3AT
- England, United Kingdom
Corporate Office
- The Bennet Building (B930)
- Babraham Research Campus
- Cambridge CB22 3AT
- England, United Kingdom
Kymab Valuation & Funding
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
6. Merger/Acquisition | 08-Apr-2021 | $1.45B | Completed | Generating Revenue | ||
5. Later Stage VC | 24-Jun-2019 | Completed | Clinical Trials - General | |||
4. Grant | 09-Jan-2017 | Completed | Clinical Trials - General | |||
3. Later Stage VC (Series C) | 24-Nov-2016 | Completed | Clinical Trials - General | |||
2. Later Stage VC (Series B) | 05-Jun-2015 | $89.1M | $119M | Completed | Clinical Trials - General | |
1. Early Stage VC (Series A) | 13-Jul-2010 | $30.1M | $30.1M | Completed | Startup |
Kymab Cap Table
Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
---|---|---|---|---|---|---|---|---|
Convertible Preferred | ||||||||
Convertible Preferred | ||||||||
Series C | ||||||||
Series B | 30,403,646 | $0.001266 | $2.44 | $2.44 | 1x | $2.44 | 22.6% | |
Series A | 20,090,000 | $0.001266 | $1.27 | $1.27 | 1x | $1.27 | 14.93% |
Kymab Comparisons
Industry
Financing
Details
Kymab Competitors (96)
One of Kymab’s 96 competitors is Adaptimmune Therapeutics, a Formerly VC-backed company based in Abingdon, United Kingdom.
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
Adaptimmune Therapeutics | Formerly VC-backed | Abingdon, United Kingdom | ||||
Memo Therapeutics | Venture Capital-Backed | Schlieren, Switzerland | ||||
Nektar Therapeutics | Formerly VC-backed | San Francisco, CA | ||||
Metacrine | Formerly VC-backed | San Diego, CA | ||||
NexImmune | Formerly VC-backed | Gaithersburg, MD |
Kymab Patents
Kymab Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
US-20240392021-A1 | Pharmaceutical formulations containing anti-ox40l antibodies | Pending | 14-Apr-2023 | ||
US-20240294651-A1 | Antibodies | Pending | 30-Jan-2023 | ||
GB-202204291-D0 | Treatment of atopic dermatitis | Inactive | 25-Mar-2022 | ||
GB-202204211-D0 | Treatment of atopic dermatitis | Inactive | 24-Mar-2022 | ||
GB-202117101-D0 | Antibodies for use as therapeutics against bacterial infections | Inactive | 26-Nov-2021 |
Kymab Signals
Kymab Former Investors (8)
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
---|---|---|---|---|
Bill & Melinda Gates Foundation | Not-For-Profit Venture Capital | Minority | ||
Cygnum Capital | Merchant Banking Firm | Minority | ||
LifeArc | Venture Capital | Minority | ||
Malin Corporation | Venture Capital | Minority | ||
ORI Capital | Venture Capital | Minority |
Affiliates
Subsidiaries (1)
Name | Industry | Location | Year Founded |
---|---|---|---|
14M Genomics | Cambridge, United Kingdom | 2014 |
Kymab FAQs
-
When was Kymab founded?
Kymab was founded in 2010.
-
Where is Kymab headquartered?
Kymab is headquartered in Cambridge, United Kingdom.
-
What is the size of Kymab?
Kymab has 141 total employees.
-
What industry is Kymab in?
Kymab’s primary industry is Drug Discovery.
-
Is Kymab a private or public company?
Kymab is a Private company.
-
What is the current valuation of Kymab?
The current valuation of Kymab is
. -
What is Kymab’s current revenue?
The current revenue for Kymab is
. -
How much funding has Kymab raised over time?
Kymab has raised $258M.
-
Who are Kymab’s investors?
Bill & Melinda Gates Foundation, Cygnum Capital, LifeArc, Malin Corporation, and ORI Capital are 5 of 8 investors who have invested in Kymab.
-
Who are Kymab’s competitors?
Adaptimmune Therapeutics, Memo Therapeutics, Nektar Therapeutics, Metacrine, and NexImmune are some of the 96 competitors of Kymab.
-
When was Kymab acquired?
Kymab was acquired on 08-Apr-2021.
-
Who acquired Kymab?
Kymab was acquired by Sanofi.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »